Novo Nordisk A/S $NVO Holdings Decreased by Farmers & Merchants Trust Co of Chambersburg PA

Farmers & Merchants Trust Co of Chambersburg PA lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 49.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,688 shares of the company’s stock after selling 2,626 shares during the period. Farmers & Merchants Trust Co of Chambersburg PA’s holdings in Novo Nordisk A/S were worth $186,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in NVO. Revolve Wealth Partners LLC lifted its position in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. Toronto Dominion Bank lifted its position in shares of Novo Nordisk A/S by 494.1% in the fourth quarter. Toronto Dominion Bank now owns 88,295 shares of the company’s stock worth $7,595,000 after buying an additional 73,432 shares during the last quarter. Waverly Advisors LLC lifted its position in shares of Novo Nordisk A/S by 105.4% in the fourth quarter. Waverly Advisors LLC now owns 13,929 shares of the company’s stock worth $1,198,000 after buying an additional 7,147 shares during the last quarter. Harmony Asset Management LLC lifted its position in shares of Novo Nordisk A/S by 1.6% in the fourth quarter. Harmony Asset Management LLC now owns 61,777 shares of the company’s stock worth $5,314,000 after buying an additional 950 shares during the last quarter. Finally, Pinkerton Retirement Specialists LLC lifted its position in shares of Novo Nordisk A/S by 1.3% in the fourth quarter. Pinkerton Retirement Specialists LLC now owns 25,247 shares of the company’s stock worth $2,172,000 after buying an additional 317 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on NVO shares. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 20th. Rothschild & Co Redburn raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. Six research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $81.00.

Novo Nordisk A/S Trading Up 1.7%

NVO stock opened at $58.20 on Thursday. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $135.20. The firm has a market cap of $259.86 billion, a P/E ratio of 15.99, a P/E/G ratio of 2.17 and a beta of 0.66. The business’s 50 day moving average is $57.21 and its 200-day moving average is $65.81. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Investors of record on Monday, August 18th were given a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio is 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.